Document Detail

Intermedin as a prognostic factor for major adverse cardiovascular events in patients with ST-segment elevation acute myocardial infarction.
MedLine Citation:
PMID:  24969626     Owner:  NLM     Status:  Publisher    
Intermedin functions systemically as a potent vasodilator and its plasma levels have been shown to be elevated in patients with acute myocardial infarction. This study aimed to evaluate the prognostic value of plasma intermedin level in the patients with ST-segment elevation acute myocardial infarction. Plasma intermedin concentrations of 128 patients and 128 healthy controls were determined using a radioimmunoassay. Patients were followed up for 6 months for major adverse cardiovascular events (MACE) consisting of cardiovascular mortality, reinfarction, hospitalization for decompensated heart failure, and lift-threatening arrhythmia. The association of plasma intermedin levels with MACE was investigated by univariate and multivariate analyses. Plasma intermedin levels were significantly higher in patients than in healthy subjects. Elevated plasma level of intermedin was identified as an independent predictor of MACE. Receiver operating characteristic curve analysis showed that plasma intermedin levels had high predictive value for MACE. Moreover, its predictive value was similar to Global Registry of Acute Coronary Events scores' based on area under curve. Meantime, it obviously improved Global Registry of Acute Coronary Events scores' predictive value in a combined logistic-regression model. In multivariate Cox's proportional hazard analysis, plasma intermedin level emerged as an independent predictor of MACE-free survival. Thus, our results suggest that high plasma intermedin level is associated with poor outcomes of patients and may be a useful prognostic biomarker in ST-segment elevation acute myocardial infarction.
Bei Tang; Ze Zhong; Hong-Wei Shen; Hui-Ping Wu; Peng Xiang; Bin Hu
Related Documents :
22998006 - Paradoxical coronary embolism, a rare cause of acute myocardial infarction on positive ...
14730006 - An antiarrhythmic effect of a chymase inhibitor after myocardial infarction.
12566116 - Increased expression of cardiac angiotensin ii type 1 (at(1)) receptors decreases myoca...
19025896 - Pharmacokinetic modeling of delayed gadolinium enhancement in the myocardium.
20507236 - Ace2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat mo...
8058576 - Predominant myocardial sarcoidosis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-6-23
Journal Detail:
Title:  Peptides     Volume:  -     ISSN:  1873-5169     ISO Abbreviation:  Peptides     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-6-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8008690     Medline TA:  Peptides     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014. Published by Elsevier Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of context in neurotensin-induced sensitization to the locomotor stimulant effect of amphetamin...
Next Document:  Effects of surface defects on two-dimensional electron gas at NdAlO3/SrTiO3 interface.